Silver Book Fact

Savings associated with t-PA treatment for ischemic stroke patients

A $600 net savings is associated with each ischemic stroke patient treated with t-PA. In 2005, only 2% of all ischemic stroke patients received t-PA. If that percentage was increased to 4% the realized cost savings would be approximately $15 million. If increased to 20%, the savings would be around $74 million.

Demaerschalk, BM and TR Yip. Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States. Stroke. 2005; 36(11): 2500-3. http://stroke.ahajournals.org/cgi/content/full/36/11/2500

Reference

Title
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Publication
Stroke
Publication Date
2005
Authors
Demaerschalk, BM and TR Yip
Volume & Issue
Volume 36, Issue 11
Pages
2500-3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Satisfaction rates of heart valve disease patients with their treatment
     
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Compared to predicted levels in the absence of drug therapy, there were 9% fewer deaths from major cardiovascular disease in 2001 and 38% and 25% fewer hospital discharges for stroke…  
  • Because of reduced mortality rates, the number of stroke survivors who are non-institutionalized increased from 2.0 to 2.4 million between 1980 and 1991.  
  • According to the National Institutes of Health, use of the clot-busting drug t-PA saves $4,400 per patient in hospitalization and nursing home costs.